Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer
|ClinicalTrials.gov Identifier: NCT00002507|
Recruitment Status : Completed
First Posted : August 10, 2004
Last Update Posted : July 25, 2013
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether combining mitomycin or porfiromycin with radiation therapy is more effective in treating patients with head and neck cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy plus either mitomycin or porfiromycin in treating patients with head and neck cancer.
|Condition or disease||Intervention/treatment||Phase|
|Carcinoma of Unknown Primary Head and Neck Cancer||Drug: mitomycin C Drug: porfiromycin Radiation: brachytherapy Radiation: radiation therapy||Phase 3|
OBJECTIVES: I. Compare the efficacy of mitomycin vs. porfiromycin as an adjunct to radiotherapy for the treatment of epidermoid carcinomas of the head and neck.
OUTLINE: Randomized study. Arm I: Radiotherapy plus Single-Agent Chemotherapy. Irradiation of involved head and neck sites by external-beam radiotherapy (EBRT) alone (source not specified), brachytherapy alone (using permanent or removable radiation sources), or both; plus Mitomycin, MITO, NSC-26980. Arm II: Radiotherapy plus Single-Agent Chemotherapy. Radiotherapy as in Arm I; plus Porfiromycin, NSC-56410.
PROJECTED ACCRUAL: Approximately 200 patients will be entered over 3-4 years.
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||RADIATION WITH MITOMYCIN C OR PORFIROMYCIN IN THE TREATMENT OF CANCER OF THE HEAD AND NECK AREA|
|Study Start Date :||November 1992|
|Actual Primary Completion Date :||October 2002|
|Actual Study Completion Date :||October 2002|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002507
|United States, Connecticut|
|Yale Comprehensive Cancer Center|
|New Haven, Connecticut, United States, 06520-8028|
|Study Chair:||James J. Fischer, MD, PhD||Yale University|